Becton Dickinson and Co (BDX) Position Lifted by Wealthsource Partners LLC

Share on StockTwits

Wealthsource Partners LLC grew its position in Becton Dickinson and Co (NYSE:BDX) by 161.6% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 5,318 shares of the medical instruments supplier’s stock after purchasing an additional 3,285 shares during the period. Wealthsource Partners LLC’s holdings in Becton Dickinson and were worth $1,274,000 at the end of the most recent quarter.

Other hedge funds have also recently modified their holdings of the company. Bartlett & Co. LLC increased its holdings in shares of Becton Dickinson and by 2,900.0% during the 2nd quarter. Bartlett & Co. LLC now owns 450 shares of the medical instruments supplier’s stock valued at $108,000 after acquiring an additional 435 shares during the last quarter. BDO Wealth Advisors LLC increased its holdings in shares of Becton Dickinson and by 361.6% during the 1st quarter. BDO Wealth Advisors LLC now owns 577 shares of the medical instruments supplier’s stock valued at $125,000 after acquiring an additional 452 shares during the last quarter. Kaizen Advisory LLC increased its holdings in shares of Becton Dickinson and by 155.9% during the 2nd quarter. Kaizen Advisory LLC now owns 609 shares of the medical instruments supplier’s stock valued at $146,000 after acquiring an additional 371 shares during the last quarter. Bay Colony Advisory Group Inc d b a Bay Colony Advisors acquired a new position in shares of Becton Dickinson and during the 2nd quarter valued at about $163,000. Finally, Karp Capital Management Corp acquired a new position in shares of Becton Dickinson and during the 1st quarter valued at about $177,000. 86.73% of the stock is currently owned by institutional investors.

Shares of NYSE:BDX opened at $254.37 on Friday. The company has a quick ratio of 0.81, a current ratio of 1.23 and a debt-to-equity ratio of 0.95. Becton Dickinson and Co has a twelve month low of $191.53 and a twelve month high of $263.37. The company has a market cap of $68.41 billion, a P/E ratio of 26.83, a price-to-earnings-growth ratio of 1.74 and a beta of 1.10.

Becton Dickinson and (NYSE:BDX) last announced its quarterly earnings data on Thursday, August 2nd. The medical instruments supplier reported $2.91 EPS for the quarter, topping the Zacks’ consensus estimate of $2.86 by $0.05. Becton Dickinson and had a return on equity of 14.16% and a net margin of 4.73%. The company had revenue of $4.28 billion during the quarter, compared to the consensus estimate of $4.25 billion. During the same quarter last year, the company earned $2.46 EPS. The company’s quarterly revenue was up 41.0% on a year-over-year basis. equities research analysts forecast that Becton Dickinson and Co will post 11.01 earnings per share for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, September 28th. Shareholders of record on Friday, September 7th will be given a $0.75 dividend. The ex-dividend date of this dividend is Thursday, September 6th. This represents a $3.00 dividend on an annualized basis and a dividend yield of 1.18%. Becton Dickinson and’s dividend payout ratio is currently 31.65%.

A number of research analysts have recently commented on BDX shares. KeyCorp reissued a “buy” rating and set a $264.00 price objective on shares of Becton Dickinson and in a report on Friday, August 3rd. ValuEngine raised Becton Dickinson and from a “hold” rating to a “buy” rating in a report on Tuesday, June 26th. Citigroup increased their price objective on Becton Dickinson and from $274.00 to $283.00 and gave the company a “buy” rating in a report on Wednesday, August 8th. Royal Bank of Canada reissued a “hold” rating and set a $248.00 price objective on shares of Becton Dickinson and in a report on Friday, August 3rd. Finally, Wells Fargo & Co increased their price objective on Becton Dickinson and from $275.00 to $290.00 and gave the company an “outperform” rating in a report on Thursday. They noted that the move was a valuation call. Four research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. Becton Dickinson and has a consensus rating of “Buy” and an average price target of $251.64.

Becton Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. It operates in two segments, BD Medical and BD Life Sciences. The BD Medical segment offers syringes, pen needles, and other products for diabetes; needles, syringes, and intravenous catheters for medication delivery; prefilled IV flush syringes; regional anesthesia needles and trays; sharps disposal containers; closed-system transfer devices; skin antiseptic products; surgical and laparoscopic instrumentations; intravenous medication safety and infusion therapy delivery, and automated medication dispensing and supply management systems; medication inventory optimization and tracking systems; and prefillable drug delivery systems.

Featured Article: Price to Earnings Ratio (PE), For Valuing Stocks

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply